Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Kyowa Hakko Kirin Co Ltd    4151   JP3256000005

KYOWA HAKKO KIRIN CO LTD (4151)
My previous session
Most popular
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Kyowa Hakko Kirin : signs drug discovery deal with AI firm InveniAI

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/12/2019 | 03:49am EST

Japanese pharma and biotech firm Kyowa Hakko Kirin is joining the growing trend of investing in artificial intelligence to bolster drug discovery efforts, entering a new partnership with AI and machine learning firm InveniAI.

KHK hopes to utilise InveniAIs AlphaMeld technology to discover how its existing pipeline products can be applied to other indications.

While the exact financial details of the deal were not disclosed, it was confirmed that an upfront sum will be paid to InveniAI, as well as a number of development and commercialisation payments.

As we seek to fulfil our business vision to bring innovative treatments to patients faster, we very much expect that InveniAIs platform, will not only enable us to identify alternate therapeutic value for our portfolio at an unprecedented speed, but also capitalize on our existing investment by reducing the time to market, clinical cost of development and enhancing the probability of clinical success, commented Dr Mitsuo Satoh, KHKs Executive Officer, Vice President, Head, R&D Division.

Dr Krishnan Nandabalan, CEO and President of InveniAI, also remarked on the deal: We are extremely pleased to initiate this collaboration to build on Kyowa Hakko Kirins clinically rich pipeline. AlphaMeld has industrialised the process of drug re-innovation by enabling the identification of complex associations between drugs/mechanisms and disease indications. The platform is patient-validated where multiple drug concepts have progressed through to human proof of clinical development.

The company follows in the steps of a number of other industry players to sign similar AI drug discovery deals, including Novo Nordisk and UK-based e-Therapeutics, and Pfizer and CytoReason.

(c) 2003-2019 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Stocks mentioned in the article
ChangeLast1st jan.
KIRIN HOLDINGS CO LTD 0.70% 2517.5 End-of-day quote.11.72%
KYOWA HAKKO KIRIN CO LTD -0.47% 2106 End-of-day quote.3.90%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on KYOWA HAKKO KIRIN CO LTD
01/12KYOWA HAKKO KIRIN : signs drug discovery deal with AI firm InveniAI
AQ
01/07KYOWA HAKKO KIRIN : Submits Application for Approval of Burosumab for FGF23-rela..
PU
2018KYOWA HAKKO KIRIN CO LTD : Ex-dividend day for final dividend
FA
2018KYOWA HAKKO KIRIN : InveniAI Enters Strategic Artificial Intelligence Collaborat..
AQ
2018Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita (buros..
AQ
2018KYOWA HAKKO KIRIN : Ultragenyx and Kyowa Kirin Announce Health Canada Approval o..
PU
2018KYOWA HAKKO KIRIN : EU approves Kyowa Kirins drug for rare lymphoma
AQ
2018KYOWA HAKKO KIRIN : Glaxo Inks Marketing Deal for Anaemia Candidate in Japan
AQ
2018KYOWA HAKKO KIRIN : Kirin Announces POTELIGEO Receives Marketing Authorisation i..
AQ
2018KYOWA HAKKO KIRIN : Kirin Announces POTELIGEO® Receives Marketing Authorisation ..
PU
More news
Financials (JPY)
Sales 2018 341 B
EBIT 2018 -
Net income 2018 52 837 M
Finance 2018 50 783 M
Yield 2018 1,41%
P/E ratio 2018 21,95
P/E ratio 2019 26,91
EV / Sales 2018 3,43x
EV / Sales 2019 3,19x
Capitalization 1 220 B
Chart KYOWA HAKKO KIRIN CO LTD
Duration : Period :
Kyowa Hakko Kirin Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KYOWA HAKKO KIRIN CO LTD
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 2 613  JPY
Spread / Average Target 23%
EPS Revisions
Managers
NameTitle
Nobuo Hanai Chairman & Chief Executive Officer
Masashi Miyamoto President, COO & Representative Director
Mitsuo Satoh Executive Officer, GM-Research & Development
Toshifumi Mikayama Director & Senior Managing Executive Officer
Yoshiko Leibowitz Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
KYOWA HAKKO KIRIN CO LTD3.90%11 146
ABBVIE-2.92%134 627
MERCK KGAA0.09%13 287
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD4.54%8 065
JAZZ PHARMACEUTICALS PLC4.12%7 786
CONVATEC GROUP1.87%3 579